Combined chemotherapy with carboplatin plus irinotecan showed favorable effi cacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis
Introduction
Small cell carcinoma of the prostate (SCCP) is rare, accounting for just 0.5% to 2% of all prostatic malignant tumors. 1 In general, the clinical features of SCCP include visceral metastases, a high incidence of osteolytic bone lesions, unresponsiveness to hormone therapy, a decreased level of serum prostate-specifi c antigen (PSA), and a high response rate to cisplatin plus etoposide chemotherapy. 2, 3 The prognosis of SCCP is poor, with a median survival range of 5 to 17.5 months, 1 and the optimal treatment, especially in relapsed chemotherapy-treated patients, is not clearly established.
We report a case of refractory relapsed small cell carcinoma of the prostate, complicated with meningeal carcinomatosis, in which combined chemotherapy with carboplatin plus irinotecan was effective.
Case report
We report the case of a 65-year-old Japanese man with a history of recurrent prostate cancer who presented with carcinomatosis.
At the age of 64 years, in August 2007, he had complained of back pain and was subsequently hospitalized in September 2007. He reported having smoked about 40 cigarettes a day for at least 25 years before the age of 45 and had no family history of prostate cancer. Pathological diagnosis, using a prostate needle biopsy, was mixed small cell carcinoma and adenocarcinoma of the prostate (Fig. 1) . The small cell carcinoma showed positive staining for CD56, chro mogranin A, and synaptophysin, and mixed components of adenocarcinoma (Gleason score 4 + 5 = 9). The clinical stage was T4N1M1 (primary prostate tumor with Abstract We report the case of a 65-year-old man with recurrent prostate cancer who presented with meningeal carcinomatosis. In September 2007, he had been diagnosed with mixed type small cell carcinoma and adenocarcinoma at clinical stage T4N1M1 (primary prostate tumor with multiple bone, liver, and lymph node metastases) and hormonal therapy had been administered. Following an increase in the level of pro-gastrin-releasing peptide (ProGRP), combined chemotherapy with cisplatin plus etoposide was implemented and showed effi cacy in targeting the small cell carcinoma. In March 2008, he presented with signs of meningeal irritation; his condition deteriorated quickly and multiple brain metastases were confi rmed by magnetic resonance imaging (MRI). A sample of cerebrospinal fl uid collected by lumbar puncture showed cancer cells and an elevated level of ProGRP. Small cell carcinoma of the prostate complicated with meningeal carcinomatosis was diagnosed. A different chemotherapy regimen was then administered, consisting of a combination of carboplatin plus irinotecan, which is one of the most common fi rst-line treatments for extensive-stage small cell lung carcinoma. From day 20 after the initiation of this therapy, he gradually recovered from the signs of meningeal irritation, and brain MRI showed nearly normal fi ndings; also, the serum level of ProGRP was reduced. In conclusion, we report the effi cacy of combined treatment with carboplatin plus irinotecan for small cell carcinoma of the prostate complicated with meningeal carcinomatosis. Because this clinical condition is extremely rare, a gold standard treatment has yet to be established. multiple osteolytic bone, liver, and lymph node metastases), and laboratory values for serum PSA and pro-gastrinreleasing peptide (ProGRP) were elevated, at 176.77 ng/ml and 544 pg/ml, respectively.
In September 2007, treatment with dual hormonal therapy using a gonadotropin-releasing hormone (GnRH) agonist and an oral androgen receptor antagonist was commenced. His serum PSA levels subsequently became undetectable and the primary tumor and metastatic lesions showed marked shrinkage. However, in October 2007, his serum ProGRP levels had increased gradually up to 1660 pg/ ml and the primary tumor and metastatic lesions had expanded. Consequently, the oral androgen receptor antagonist was discontinued and he was treated with the GnRH agonist concurrently with cisplatin plus etoposide, targeting small cell carcinoma. This treatment regimen was effective and regression of the primary and metastatic tumors was observed. His serum ProGRP level decreased to 40.2 pg/ml.
In March 2008, he had a relapse, with signs of meningeal irritation, including headache, frequent vomiting, and a decreased level of consciousness, and his condition deteriorated quickly. In April 2008, he was re-hospitalized. His serum ProGRP level had increased again, to 1658 pg/ml; however, his level of serum PSA was little changed. Magnetic resonance imaging (MRI) revealed multiple brain metastases and meningeal carcinomatosis, related to the meningeal irritation. A lumbar puncture was performed to collect a sample of cerebrospinal fl uid (CSF) for analysis. Atypical cells with a high nuclear/cytoplasmic ratio and coarse chromatin were detected (Fig. 2) and an elevated ProGRP level (4665 pg/ml) was revealed, although the PSA level in the CSF sample and a serum sample was undetectable. In accordance with these fi ndings, small cell carcinoma of prostate, complicated with meningeal carcinomatosis was diagnosed. However, the time to progression was just 1 month after four cycles of the previous combination chemotherapy, and his performance status had decreased from 1 to 3. We recommended that he receive best supportive care; however, he and his family desired other treatment. 
Discussion
Meningeal carcinomatosis in prostate cancer is relatively rare. The incidence has been reported as less than 5% in patients with prostate cancer, particularly in those with terminal-stage disease. 4 The gold standard for the diagnosis of meningeal carcinomatosis is dependent on the cytological examination of malignant cells in CSF. Unfortunately, false-negative results are common, and the positive rate for all types of tumors is around 50%-60% with one sample; 80% with two; and 90% with three. 5 However, even multiple CSF samples may fail to yield an accurate diagnosis, leading to protracted clinical uncertainty for some patients. It has been speculated that the cause of the false-negative cytology may be the obstruction of CSF fl ow, inadequate amounts of CSF, or delayed handling of cytology specimens. 6 Of imaging methods, gadolinium-enhanced MRI has high sensitivity and specifi city for abnormal fi ndings with meningeal carcinomatosis, although a false-negative rate of up to 30% has been reported. 7 In the present patient, gadolinium-enhanced brain MRI clearly presented enhancement of the meninx along the cerebral sulci, and these fi ndings were useful for the evaluation of abnormal fi ndings and the patient's clinical course. However, imaging methods alone cannot render a defi nitive diagnosis. Therefore, a novel surrogate marker is needed for the diagnosis of meningeal carcinomatosis, and it is extremely important to defi ne the cancer type as well as determine the presence of any malignancy; for example, in order to make the differential diagnosis of double primary cancer or mixedtype cancer.
Recently, ProGRP was reported to be a useful and sensitive marker for SCCP as well as small cell lung cancer (SCLC). 8 Pedersen et al. 9 demonstrated that an elevated level of ProGRP in CSF was useful to diagnose meningeal metastases of small cell carcinoma. Castro et al. 10 reported a patient with small cell carcinoma of unknown primary site, in whom the ProGRP level in CSF was elevated by more than six orders of magnitude above the serum level B A   Fig. 3A,B 
In the present patient, the ProGRP level in CSF was elevated to 4665 pg/ml, almost three orders of magnitude above the serum level (1658 pg/ml). Thus, a diagnosis of meningeal carcinomatosis in patients with SCCP may be established by elevated ProGRP levels in CSF samples. To our knowledge, this is the fi rst report of SCCP with meningeal carcinomatosis monitored by elevated ProGRP levels in CSF as well as in serum.
Hormone therapy for SCCP is ineffective, except for mixed-type with adenocarcinoma. 11 The current recommended chemotherapy regimens for SCCP are platinumbased, similar to those used for SCLC, because SCCP has demonstrated similarity to SCLC in morphologic features 12 and in the expression phenotype pattern of some genes. 13 Of the recommended chemotherapy regimens, combined chemotherapy with cisplatin plus etoposide is the most common. A phase II trial of doxorubicin combined with this regimen for SCCP showed more toxicity than cisplatin plus etoposide only, and did not show longer survival. 2 Other reports have shown that amrubicin or combination chemotherapy with a gemcitabine, docetaxel, and carboplatin regimen may be alternative candidates for fi rst induction chemotherapy for patients with SCCP. 7, 14 Chemotherapy has been of limited value in patients with brain metastases because of the blood brain barrier (BBB). Candidate drugs acting on the central nervous system (CNS) have a poor success rate, and more than 98% of such drugs cannot cross the BBB. 15 In patients with glioma, carboplatin was detectable in the CSF beginning 0.5 h after the initiation of infusion, and it was then slowly eliminated. The mean maximum CSF concentration of carboplatin was 15.25% of that in plasma. 16 In preclinical studies, irinotecan has demonstrated cytotoxic activity against CNS tumor xenografts. 17 Combined chemotherapy with carboplatin and irinotecan was an effective treatment for SCLC brain metastases. 18 We chose combined chemotherapy with carboplatin plus irinotecan for the present patient with refractory disease with meningeal irritation, in consideration of his poor performance status and relapse at only 1 month into treatment with cisplatin and etoposide. Fortunately, he responded favorably to the treatment and showed improved quality of life and performance status.
In extended disease (ED) SCLC, cisplatin plus irinotecan was compared with cisplatin plus etoposide in a randomized phase III trial and showed a better survival rate for patients with good performance status. 19 In contrast, carboplatin is known to have activity similar to that of cisplatin but to exhibit a more favorable toxicity profi le; it is widely used as a practical substitute for cisplatin in ovarian cancer and ED-SCLC. To date, combination chemotherapy of carboplatin and irinotecan has been shown to be a convenient, tolerable, and effective treatment in several phase II trials of untreated extensive-stage SCLC. 20, 21 In addition, high effi cacy of carboplatin and irinotecan has been demonstrated in phase II trials for SCLC patients with refractory or relapsed disease. 22, 23 In the present study, we have reported a rare case of SCCP complicated with meningeal carcinomatosis in a patient in whom combined treatment with carboplatin plus irinotecan was effective. Therefore, this combined regimen could be promising for patients with relapsed meningeal carcinomatosis with poor performance status or old age.
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